Q2 25 EPS
$-1.00
BEAT +8.37%
Est. $-1.09
Q2 25 Revenue
$8.5M
MISS 36.31%
Est. $13.3M
vs S&P Since Q2 25
+70.9%
BEATING MARKET
BEAM +89.5% vs S&P +18.6%
Market Reaction
Did BEAM Beat Earnings? Q2 2025 Results
Beam Therapeutics delivered a mixed second quarter, beating Wall Street's loss expectations while falling well short on revenue as the gene editing company continues funneling capital into its clinical pipeline. The company posted a loss of $1.00 per… Read more Beam Therapeutics delivered a mixed second quarter, beating Wall Street's loss expectations while falling well short on revenue as the gene editing company continues funneling capital into its clinical pipeline. The company posted a loss of $1.00 per share, coming in 8.37% better than the consensus estimate of $1.09, but revenue of $8.47 million missed forecasts by 36.31% and slid 28.1% from the year-ago quarter's $11.77 million, reflecting lower license and collaboration payments. The primary driver of the wider absolute net loss, which widened to $102.29 million from $91.05 million a year ago, was a 17% surge in R&D spending to $101.76 million as Beam advanced both BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-101 for sickle cell disease through active Phase 1/2 trials. Analysts tracking the company have maintained a constructive view on the pipeline's potential, citing the FDA's RMAT designation for BEAM-302 as a positive signal. With $1.15 billion in cash, Beam projects its runway extending into 2028, with key data readouts for BEAM-101 expected by year-end and a BEAM-302 clinical update targeted for early 2026.
Key Takeaways
- • Increased R&D spending driven by advancing multiple clinical-stage programs
- • Higher other income partially offsetting operating losses
- • Capital raises in early 2025 significantly strengthening balance sheet
BEAM YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
“In the first half of 2025, we made significant clinical, operational and regulatory progress across each of our high-priority programs, and we aim to harness this momentum heading into key catalysts at the end of 2025 and early next year. We have now dosed 30 patients in the BEACON trial of BEAM-101, which has a potential best-in-class profile as a one-time therapy for severe sickle cell disease, marking an important milestone on our path to a BLA filing. We look forward to sharing additional data from this trial later this year.”
— John Evans, Q2 2025 Earnings Press Release
BEAM Earnings Trends
BEAM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BEAM EPS Trend
Earnings per share: estimate vs actual
BEAM Revenue Trend
Quarterly revenue: estimate vs actual
BEAM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-1.01 | $-0.91 | +10.06% | $31.7M | +159.70% |
| Q4 25 BEAT FY | $-1.12 | $2.33 | +308.97% | $114.1M | +781.34% |
| FY Full Year | $-4.28 | $-0.81 | +81.08% | $139.7M | +262.99% |
| Q3 25 MISS | $-1.03 | $-1.10 | -7.10% | $9.7M | -23.79% |
| Q2 25 BEAT | $-1.09 | $-1.00 | +8.37% | $8.5M | -36.31% |
| Q1 25 MISS | $-1.17 | $-1.24 | -5.86% | $7.5M | -49.13% |